Listen Now

Paul Sargos (Institut Bergonié, France) discusses the GETUG-AFU 17 trial and Andrew Kneebone (Royal North Shore Hospital and University of Sidney, Australia) the RAVES trial.

Lisa Bodei (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses the Review in The Lancet Oncology on molecular profiling of neuroendocrine tumours to predict response to peptide receptor radionuclide therapy.

Alexander Drilon (Memorial Sloan Kettering Cancer Center, New York, NY, USA) discusses a pooled analysis in The Lancet Oncology on the role of larotrectinib in patients with TRK fusion-positive solid tumours.

Ken Herrman (University Hospital Essen, Essen, Germany) discusses a Review in The Lancet Oncology on the role of injectable radiopharmaceuticals with anti-tumour effects.

Corneel Coens and Madeline Pe discuss recommendations from the SISAQOL Consortium for the analysis of patient-reported outcomes, published in a Policy Review in The Lancet Oncology.

Monica Koo (University College London, London, UK) discusses an Article in The Lancet Oncology on presenting symptoms of cancer and stage at diagnosis in patients in England.

Rifat Atun (Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA) discusses a Review in The Lancet Oncology on global patterns in public and philanthropic funding for childhood cancer research with Senior Editor Márcia Costa.

Partha Basu (International Agency for Research on Cancer, Lyon, France) discusses a Policy Review in The Lancet Oncology on cervical cancer prevention efforts in India.

David Palma and Anthony Nichols discuss the findings from their ORATOR trial on radiotherapy or robotic surgery for oropharyngeal squamous cell carcinoma.

New Zealand’s new interim Cancer Control Agency director, Diana Sarfati, discusses a series of five papers exploring cancer control in small island nations.

Eric Deutsch (Gustave Roussy Comprehensive Cancer Center, Villejuif, France) presents The Lancet Oncology’s latest series on advances in radioimmunotherapy for cancer.

Georgina Long (The University of Sydney, Sydney, NSW, Australia) discusses three papers from The Lancet Oncology on neoadjuvant approaches for melanoma treatment.

Jens Hillengass discusses the new International Myeloma Working Group consensus guidelines on optimal use of imaging methods for monoclonal plasma cell disorders.

Kee Yuan Ngiam (National University Hospital Singapore, Singapore) discusses a duo of papers exploring big data and machine-learning algorithms for healthcare delivery and pathology in oncology.

CS Pramesh discusses ten low-value or harmful practises that should be avoided in cancer care in India.

Bianca Hoeben discusses the latest guidelines from the SIOPE radiotherapy working group on vertebral radiotherapy dose in paediatric patients.

Anna Bibby joins The Lancet Oncology to discuss recent developments in the treament of malignant plural mesothelioma.

Frederick Locke joins The Lancet Oncology to discuss long-term results from the ZUMA-1 trial on the safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma.

Talía Malagón discusses her modelling study which assesses the age at which to stop cervical cancer screening in older women and the remaining lifetime risk of cervical cancer.

Stein Kaasa and Jon Loge discuss their new Commission on palliative care.